SEC Form SC 13G filed by Denali Therapeutics Inc.

8/16/24 1:18:04 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $DNLI alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 DENALI THERAPEUTICS INC COMMON STOCK Cusip #24823R105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #24823R105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,187,242 Item 6: 0 Item 7: 7,191,945 Item 8: 0 Item 9: 7,191,945 Item 11: 5.023% Item 12: HC Cusip #24823R105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,191,945 Item 8: 0 Item 9: 7,191,945 Item 11: 5.023% Item 12: IN Item 1(a). Name of Issuer: DENALI THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 161 Oyster Point Blvd South San Francisco, CA 94080 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 24823R105 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 7,191,945 (b) Percent of Class: 5.023% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,191,945 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of DENALI THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of DENALI THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 15, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on August 15, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of DENALI THERAPEUTICS INC at August 12, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $DNLI alert in real time by email

Recent Analyst Ratings for

$DNLI

Date	Price Target	Rating	Analyst
10/10/2024		Mkt Perform	Raymond James
10/7/2024		Overweight → Neutral	Cantor Fitzgerald
12/13/2023	$32.00	Buy	Citigroup
11/20/2023	$28.00	Overweight	JP Morgan
10/24/2023	$85.00 → $35.00	Overweight	Cantor Fitzgerald
9/6/2023	$38.00	Buy	B. Riley Securities
1/30/2023	$50.00	Outperform	SVB Securities
12/5/2022		Outperform	Cowen

More analyst ratings

SEC Form SC 13G filed by Denali Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$DNLI

$DNLI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Schenkein David P exercised 47,165 shares at a strike of $18.00 and sold $1,932,665 worth of shares (59,441 units at $32.51), decreasing direct ownership by 57% to 9,220 units (SEC Form 4)

COFO and Secretary Schuth Alexander O. exercised 15,558 shares at a strike of $5.28 and sold $465,286 worth of shares (15,558 units at $29.91) (SEC Form 4)

Director Sato Vicki L sold $30,600 worth of shares (1,020 units at $30.00), decreasing direct ownership by 0.91% to 111,056 units (SEC Form 4)

$DNLI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on Denali Therapeutics

Denali Therapeutics downgraded by Cantor Fitzgerald

Citigroup initiated coverage on Denali Therapeutics with a new price target

$DNLI
Press Releases

Fastest customizable press release news feed in the world

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

$DNLI
Market Insights

Live Market Insights

JP Morgan Maintains Overweight on Denali Therapeutics, Raises Price Target to $29

'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News

Denali Therapeutics shares are trading shares are trading higher after the FDA selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.

$DNLI
Leadership Updates

Live Leadership Updates

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

$DNLI
Large Ownership Changes

This live feed shows all institutional transactions in real time.